Cereno Scientific

The following main resolutions were resolved at the general meeting:

Determining the number of directors and deputy directors

The general meeting resolved, in accordance with shareholders’ proposal, that the board of directors for the period until the next annual general meeting shall consist of six (6) board members without deputies.

Determination of remuneration to the board of directors

The general meeting resolved, in accordance with shareholders' proposal, that the remuneration to the board of directors for the period from the annual general meeting 2023 until the end of the annual general meeting 2024 shall amount to a total of SEK 1,260,000 distributed as follows: remuneration of three (3) price base amounts to each of the board members and nine (9) price base amounts to the chairman of the board of directors.

Election of the board of directors

The general meeting resolved, in accordance with shareholders' proposal, to re-elect the existing board members Jonas Faijerson Säljö, Sverker Jern, Lena Mårtensson Wernrud, Anders Svensson, and Joakim Söderström and to elect Jeppe Øvlesen as a new board member. The general meeting also resolved to re-elect Joakim Söderström as chairman of the board of directors.

Resolution on a directed issue of warrants to a board member

The general meeting resolved, in accordance with shareholders' proposal, on a directed issue of warrants of series 2023/2026:3 to the new board member Jeppe Øvlesen.

Resolution on a directed issue of warrants and adoption of an incentive program

The general meeting resolved, in accordance with the board of directors’ proposal, on a directed issue of warrants of series 2023/2026:4 to the company with the right and obligation to transfer warrants to current employee of the company.

The full proposals are available on the company's website (www.cerenoscientific.com).

For further information, please contact:

Eva Jagenheim, CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.